- Home
- DCBO vs DYN Comparison
DCBO vs DYN Comparison
Compare DCBO & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCBO
- DYN
- Stock Information
- Founded
- DCBO 2016
- DYN 1984
- Country
- DCBO Canada
- DYN United States
- Employees
- DCBO N/A
- DYN N/A
- Industry
- DCBO
- DYN Medicinal Chemicals and Botanical Products
- Sector
- DCBO
- DYN Health Care
- Exchange
- DCBO Nasdaq
- DYN Nasdaq
- Market Cap
- DCBO 893.8M
- DYN 848.8M
- IPO Year
- DCBO 2020
- DYN 2020
- Fundamental
- Price
- DCBO $31.94
- DYN $11.06
- Analyst Decision
- DCBO Strong Buy
- DYN Strong Buy
- Analyst Count
- DCBO 7
- DYN 12
- Target Price
- DCBO $48.14
- DYN $47.73
- AVG Volume (30 Days)
- DCBO 88.0K
- DYN 2.8M
- Earning Date
- DCBO 05-09-2025
- DYN 05-05-2025
- Dividend Yield
- DCBO N/A
- DYN N/A
- EPS Growth
- DCBO 975.00
- DYN N/A
- EPS
- DCBO 0.86
- DYN N/A
- Revenue
- DCBO $216,931,000.00
- DYN N/A
- Revenue This Year
- DCBO $13.92
- DYN N/A
- Revenue Next Year
- DCBO $14.54
- DYN N/A
- P/E Ratio
- DCBO $37.12
- DYN N/A
- Revenue Growth
- DCBO 19.96
- DYN N/A
- 52 Week Low
- DCBO $26.00
- DYN $6.36
- 52 Week High
- DCBO $53.86
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- DCBO 58.08
- DYN 58.74
- Support Level
- DCBO $28.20
- DYN $7.38
- Resistance Level
- DCBO $29.88
- DYN $11.24
- Average True Range (ATR)
- DCBO 1.46
- DYN 0.84
- MACD
- DCBO 0.57
- DYN 0.57
- Stochastic Oscillator
- DCBO 99.50
- DYN 96.31
About DCBO Docebo Inc.
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.